90
Participants
Start Date
January 8, 2020
Primary Completion Date
April 23, 2025
Study Completion Date
April 23, 2025
Maralixibat
All subjects will receive Maralixibat oral solution (up to 600 microgram per kilogram \[mcg/kg\]) twice daily
Children's Hospital at Montefiore, The Bronx
Children Hospital of Pittsburgh, Pittsburgh
Medstar Georgetown University Hospital, Washington D.C.
Azienda Ospedaliera Papa Giovanni XXIII - Unita di Pediatria, Bergamo
Medical University of South Carolina, Charleston
CHU de Toulouse - Hôpital des Enfants, Toulouse
Advent Health, Orlando
Koc University Hospital, Istanbul
Cincinnati Children's Hospital, Cincinnati
University of Texas Southwestern Medical Center, Dallas
University of Texas, Health Science Center San Antonio, San Antonio
Children's Hospital Los Angeles, Los Angeles
Seattle Children's Hospital, Seattle
Hospital Italiano de Buenos Aires, Buenos Aires
Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde, Vienna
Cliniques Universitaires Saint-Luc, Brussels
Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo
University of Alberta - Women and Children's Health Research Institute, Edmonton
Fundacion Cardioinfantil, Bogotá
Groupement Hospitalier Est Hopital, Femme Mère Enfant de Lyon, Lyon
Medizinische Hochschule, Hanover
Ospedale Pediatrico bambino Gesu', Roma
Hotel Dieu de France, Alfred Naccache, Beirut
Consultario de Joshue David Covarrubias Esquer, Zapopan
Instytut Pomnik Centrum, Zdrowia Dziecka, Warsaw
KK Women's and Children's Hospital, Singapore
Birmingham Children's Hospital, Birmingham
King's College Hospital NHS Foundation Trust, London
Lead Sponsor
Mirum Pharmaceuticals, Inc.
INDUSTRY